Tilray, Inc. (TLRY) Reports Q2 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tilray, Inc. Reports Second Quarter 2018 Earnings
August 28, 2018 4:05 PM EDTRevenue rises 95.2% to US$9.7 million in second quarter and 75.2% to US$17.6 million in first half of 2018 Tilray medical cannabis products now available to patients in 11 countries on five continents Company has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories Significant progress achieved in expanding Companys global production capacity
NANAIMO, British Columbia--(BUSINESS WIRE)-- Tilray,Inc., (Tilray or the Company) (NASDAQ: TLRY) a global pioneer in cannabis... More
